09/06/2026
PASID & American Diabetes Association 2026 | Breaking News 🚨🚨🚨
Beyond GLP-1: The New Race in Obesity, Diabetes & Metabolic Liver Disease
ADA 2026 is making one thing very clear:
The future of metabolic medicine is no longer about GLP-1 alone.
We are now entering the era of:
-Dual agonists
-Triple agonists
-Amylin-based combinations
-Oral small-molecule GLP-1 therapies
-Liver-targeted obesity treatments
Here are four major programs to watch closely:
1. Survodutide — Boehringer Ingelheim / Zealand Pharma
Mechanism: Dual glucagon/GLP-1 receptor agonist
Key trials: SYNCHRONIZE-1 and SYNCHRONIZE-MASLD
Survodutide is particularly exciting because it is not only a weight-loss therapy; it may also become a major player in MASLD/MASH, where obesity, diabetes, insulin resistance, and liver disease overlap.
In SYNCHRONIZE-1, survodutide achieved significant weight loss in people with obesity or overweight without diabetes, with reported mean weight loss up to 16.6% after 76 weeks.
The liver angle is what makes this drug different. With the rapid rise of MASLD and MASH, the next generation of obesity therapies may be judged not only by weight reduction, but also by liver fat reduction, inflammation, fibrosis signals, and long-term cardiometabolic protection.
2. CagriSema — Novo Nordisk
Mechanism: Cagrilintide + semaglutide
Class: Amylin analogue + GLP-1 receptor agonist
Key trials: REIMAGINE-1, REIMAGINE-2, REIMAGINE-3
In REIMAGINE-2, once-weekly CagriSema showed HbA1c reduction of 1.91 percentage points and body-weight reduction of 14.2% in adults with type 2 diabetes, outperforming semaglutide alone in that trial.
3. Orforglipron — Eli Lilly
Mechanism: Oral non-peptide GLP-1 receptor agonist
Brand name: Foundayo
Key trials: ACHIEVE program
Orforglipron may represent one of the most practical breakthroughs in the field: an oral GLP-1 tablet without the complex fasting, water, and timing restrictions required with oral semaglutide.
The ACHIEVE program includes comparisons with:
-Dapagliflozin — ACHIEVE-2
-Oral semaglutide — ACHIEVE-3
-Placebo added to insulin glargine — ACHIEVE-5
Lilly reported that phase 3 ACHIEVE results showed orforglipron outperformed oral semaglutide and dapagliflozin in type 2 diabetes, supporting its potential to redefine oral incretin therapy.
4. AZD5004 / Elecoglipron — AstraZeneca / Eccogene
Mechanism: Oral small-molecule GLP-1 receptor agonist
Key trials: VISTA and SOLSTICE
The VISTA trial evaluates the drug in overweight/obesity, while SOLSTICE evaluates it in type 2 diabetes. SOLSTICE is a phase 2b randomized, double-blind, placebo-controlled study in adults with T2D.
This is important because the oral GLP-1 space is becoming highly competitive, and the next big disruption may not be “more weight loss” alone, but easier delivery, better scalability, and improved access.
